Edition:
India

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

34.46EUR
1:58pm IST
Change (% chg)

€0.22 (+0.64%)
Prev Close
€34.24
Open
€34.90
Day's High
€35.20
Day's Low
€34.40
Volume
131,814
Avg. Vol
504,107
52-wk High
€37.10
52-wk Low
€10.26

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.59
Market Cap(Mil.): €987.62
Shares Outstanding(Mil.): 61.42
Dividend: --
Yield (%): --

Financials

LIVE MARKETS-Three hot "special sits"

* Dow ends above 26,000 * Asian stocks hit record highs * Dollar pulls back from three-year lows Jan 18 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net THREE HOT "SPECIAL SITS" (0754 GMT) Here's the latest on 3 hot European "special sits":

1:28pm IST

Largest Ablynx shareholder says Novo Nordisk offer is too low

BRUSSELS, Jan 18 The largest shareholder in Belgian biotech group Ablynx said on Thursday that it believed a 2.6 billion euro ($3.2 billion) offer made by Denmark's Novo Nordisk was too low.

1:08pm IST

LIVE MARKETS-Closing snapshot: STOXX 600 flat

* European stocks end off highs * Cyclicals underperform after rally * UK inflation down from November peak * DAX shrugs off stronger euro Jan 16 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: STOXX 600 FLAT (1651 GMT) Euro

16 Jan 2018

LIVE MARKETS-Italy misses longest winning streak in 20 years by a whisker

* European stocks end off highs * Cyclicals underperform after rally * UK inflation down from November peak * DAX shrugs off stronger euro Jan 16 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net ITALY MISSES LONGEST WINNING STREAK IN 20 YEARS BY A

16 Jan 2018

LIVE MARKETS-Banks: one thing not to worry about (for now)

* European stocks rise * Cyclicals underperform after rally * UK inflation down from November peak * DAX shrugs off stronger euro Jan 16 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net BANKS: ONE THING NOT TO WORRY ABOUT (FOR NOW) (1533 GMT)

16 Jan 2018

LIVE MARKETS-Closing snapshot: European stocks end in positive territory, FTSE at a record

* European shares end higher * Euro rises on German coalition hopes * FTSE on new records as GKN surges * Kering to spin off Puma * Europe stock funds post inflows Jan 12 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market moves: danilo.masoni.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: EUROPEAN

12 Jan 2018

Deals of the day-Mergers and acquisitions

Jan 8 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

09 Jan 2018

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

08 Jan 2018

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

08 Jan 2018

UPDATE 6-Ablynx soars after rejects Novo Nordisk's $3.1 bln biotech bid

* Bid underlines demand for biotech assets from large firms (Updates with exit of Ablynx chairman, closing share price)

08 Jan 2018

Earnings vs. Estimates